An international survey to inform priorities for new guidelines on von Willebrand disease

被引:30
|
作者
Kalot, Mohamad A. [1 ]
Al-Khatib, Mohammed [1 ]
Connell, Nathan T. [2 ,3 ]
Flood, Veronica [4 ]
Brignardello-Petersen, Romina [5 ]
James, Paula [6 ]
Mustafa, Reem A. [1 ,5 ]
机构
[1] Univ Kansas, Med Ctr, Dept Nephrol & Hypertens, Outcomes & Implementat Res Unit, Kansas City, KS 66103 USA
[2] Brigham & Womens Hosp, Dept Med, Hematol Div, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Med Coll Wisconsin, Dept Pediat, Div Hematol Oncol, Wauwatosa, WI USA
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[6] Queens Univ, Kingston, ON, Canada
关键词
bleeding disorders; guidelines; multidisciplinary; patient engagement; stakeholders; survey; von Willebrand disease; QUALITY-OF-LIFE; CLINICAL-TRIALS; MANAGEMENT; PREVALENCE; DIAGNOSIS; HEMATOLOGY; MODERATE; HEALTH; VWD;
D O I
10.1111/hae.13881
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction von Willebrand disease (VWD) is an inherited bleeding disorder caused by a quantitative or qualitative dysfunction of von Willebrand factor. Clinicians, patients and other stakeholders have many questions about the diagnosis and management of the disease. Aim To identify topics of highest importance to stakeholders that could be addressed by guidelines to be developed by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF) and the World Federation of Hemophilia (WFH). Methods A survey to determine and prioritize topics to be addressed in the collaborative development of guidelines for VWD was distributed to international stakeholders including patients, caregivers and healthcare providers (HCPs). Representatives of the four organizations coordinated the distribution strategy. The survey focused on both diagnosis and management of VWD, soliciting 7-point Likert-scale responses and open-ended comments, in English, French and Spanish. We conducted descriptive analysis with comparison of results by stakeholder type, gender and countries' income classification for the rating questions and qualitative conventional content data analysis for the open-ended responses. Results A total of 601 participants responded to the survey (49% patients/caregivers and 51% healthcare providers). The highest priority topics identified were diagnostic criteria/classification, bleeding assessment tools and treatment options for women and surgical patients. In contrast, screening for anaemia and differentiating plasma-derived therapy versus recombinant therapies received lower ratings. Conclusion This survey highlighted areas of importance to a diverse representation of stakeholders in the diagnosis and management of VWD, providing a framework for future guideline development and implementation.
引用
收藏
页码:106 / 116
页数:11
相关论文
共 50 条
  • [1] INTERNATIONAL SURVEY OF PATIENTS WITH VON-WILLEBRAND DISEASE AND ANGIODYSPLASIA
    FRESSINAUD, E
    MEYER, D
    [J]. THROMBOSIS AND HAEMOSTASIS, 1993, 70 (03) : 546 - 546
  • [2] EUROPEAN ADOPTION OF THE VON WILLEBRAND DISEASE GUIDELINES
    Leebeek, F. W.
    [J]. HAEMOPHILIA, 2022, 28 : 11 - 11
  • [3] Von Willebrand Factor and von Willebrand disease: new approaches to diagnosis
    Ines Woods, Adriana
    Noemi Blanco, Alicia
    Catalina Kempfer, Ana
    Paiva, Juvenal
    Ines Bermejo, Emilse
    Sanchez Luceros, Analia
    Angela Lazzari, Maria
    [J]. ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2016, 50 (02): : 273 - 289
  • [5] The 2021 von Willebrand disease guidelines: Clarity and controversy
    Makris, Mike
    Hermans, Cedric
    [J]. HAEMOPHILIA, 2022, 28 (01) : 1 - 3
  • [6] Guidelines for the diagnosis and management of von Willebrand disease in Italy
    Federici, AB
    Castaman, G
    Mannucci, PM
    [J]. HAEMOPHILIA, 2002, 8 (05) : 607 - 621
  • [7] Current Diagnosis of von Willebrand Disease in Italy: 3 Years Following the Release of the International Guidelines
    Federici, Augusto B.
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2024,
  • [8] New concepts in Von Willebrand disease
    Sadler, JE
    [J]. ANNUAL REVIEW OF MEDICINE, 2005, 56 : 173 - +
  • [9] New therapies for von Willebrand disease
    Mannucci, Pier Mannuccio
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2019, : 590 - 595
  • [10] New therapies for von Willebrand disease
    Mannucci, Pier Mannuccio
    [J]. BLOOD ADVANCES, 2019, 3 (21) : 3481 - 3487